Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
L3Harris
LHX
|
+$148M |
| 2 |
GE HealthCare
GEHC
|
+$118M |
| 3 |
Atlassian
TEAM
|
+$101M |
| 4 |
Axon Enterprise
AXON
|
+$23.7M |
| 5 |
Reliance Steel & Aluminium
RS
|
+$22.4M |
Top Sells
| 1 |
Apple
AAPL
|
+$360M |
| 2 |
Microsoft
MSFT
|
+$199M |
| 3 |
GE Aerospace
GE
|
+$131M |
| 4 |
NVIDIA
NVDA
|
+$99.2M |
| 5 |
Amazon
AMZN
|
+$85.4M |
Sector Composition
| 1 | Technology | 28.64% |
| 2 | Healthcare | 14.81% |
| 3 | Consumer Discretionary | 11.76% |
| 4 | Industrials | 9.44% |
| 5 | Communication Services | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Expro
XPRO
$1.43B
| $2.8M | ﹤0.01% |
152,500
-18,100
| -11% | -$332K |
|
1627
Upbound Group
UPBD
$1.45B
| $2.8M | ﹤0.01% |
114,200
-21,600
| -16% | -$529K |
|
1628
Relay Therapeutics
RLAY
$688M
| $2.79M | ﹤0.01% |
169,700
-19,000
| -10% | -$313K |
|
1629
RadNet
RDNT
$5.69B
| $2.79M | ﹤0.01% |
111,400
-13,200
| -11% | -$330K |
|
1630
Viking Therapeutics
VKTX
$2.79B
| $2.78M | ﹤0.01% |
+166,900
| New | +$2.78M |
|
|
LGF.B
1631
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $2.77M | ﹤0.01% |
266,694
-31,300
| -11% | -$325K |
|
1632
Freedom Holding
FRHC
$10.1B
| $2.77M | ﹤0.01% |
38,500
-4,600
| -11% | -$331K |
|
1633
First Commonwealth Financial
FCF
$1.84B
| $2.76M | ﹤0.01% |
222,000
-3,500
| -2% | -$43.5K |
|
1634
MGP Ingredients
MGPI
$596M
| $2.75M | ﹤0.01% |
28,400
-3,400
| -11% | -$329K |
|
1635
Hess Midstream
HESM
$5.15B
| $2.75M | ﹤0.01% |
94,900
-11,300
| -11% | -$327K |
|
1636
US Physical Therapy
USPH
$1.22B
| $2.74M | ﹤0.01% |
28,000
-3,400
| -11% | -$333K |
|
1637
First Bancorp
FBNC
$2.29B
| $2.74M | ﹤0.01% |
77,100
-9,000
| -10% | -$320K |
|
1638
PDF Solutions
PDFS
$765M
| $2.73M | ﹤0.01% |
64,500
-6,900
| -10% | -$293K |
|
1639
IAMGOLD
IAG
$6.42B
| $2.7M | ﹤0.01% |
991,000
-113,000
| -10% | -$308K |
|
1640
La-Z-Boy
LZB
$1.39B
| $2.7M | ﹤0.01% |
92,900
-11,000
| -11% | -$320K |
|
1641
Vericel Corp
VCEL
$1.62B
| $2.69M | ﹤0.01% |
91,800
-10,700
| -10% | -$314K |
|
|
PLYA
1642
DELISTED
Playa Hotels & Resorts
PLYA
| $2.69M | ﹤0.01% |
280,300
-40,400
| -13% | -$388K |
|
1643
TriCo Bancshares
TCBK
$1.48B
| $2.69M | ﹤0.01% |
64,700
-7,700
| -11% | -$320K |
|
1644
Kforce
KFRC
$567M
| $2.69M | ﹤0.01% |
42,500
-6,100
| -13% | -$386K |
|
1645
Ligand Pharmaceuticals
LGND
$3.23B
| $2.68M | ﹤0.01% |
36,500
-4,200
| -10% | -$309K |
|
|
ARI
1646
Apollo Commercial Real Estate
ARI
$1.51B
| $2.68M | ﹤0.01% |
288,339
-34,100
| -11% | -$317K |
|
1647
DoubleVerify
DV
$2.13B
| $2.68M | ﹤0.01% |
89,000
-10,000
| -10% | -$302K |
|
|
GOGL
1648
DELISTED
Golden Ocean Group
GOGL
| $2.68M | ﹤0.01% |
284,520
-31,747
| -10% | -$299K |
|
1649
ADT
ADT
$7.24B
| $2.68M | ﹤0.01% |
370,621
-41,800
| -10% | -$302K |
|
1650
Compass Diversified
CODI
$527M
| $2.68M | ﹤0.01% |
140,200
-15,700
| -10% | -$300K |
|